You are viewing an incomplete version of our website. Please click to reload the website as full version.

Adalimumab ELISA Kit

Details for Product No. ABIN1540249, Supplier: Login to see New
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Human, Mouse (Murine), Rat (Rattus), Monkey
Methode Type Sandwich ELISA
Minimum Detection Limit 10 ng/mL
Pubmed 24 references available
Supplier Login to see New
Catalog number from supplier Login to see New
Quantity 96 tests
Shipping to United States ( )
Availability Will be delivered in 10 to 16 Business Days
Purpose Enzyme immunoassay for the quantitative determination of free adalimumab (Humira®) in serum and plasma.
Sample Type Serum, Plasma
Detection Method Colorimetric
Cross-Reactivity (Details) There is no cross reaction with native serum immunoglobulins. However, cross reaction is observed with the serum/plasma samples of patients under the treatment of other therapeutic anti-TNF antibodies such as infliximab (Remicade®) and/or etanercept (Enbrel®).
Characteristics Enzyme immunoassay for the quantitative determination of free adalimumab (Humira®) in serum and plasma. adalimumab ELISA has been especially developed for the quantitative analysis of free adalimumab in serum and plasma samples.

Recovery: Recovery rate was found to be equal and higher than 95 % with normal human serum samples with known concentrations.
  • 1 x 12 x 8 Microtiter Plate Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with reactant.
  • 5 x 0.3 mL EAdalimumab Standards A-E1000, 300, 100, 30, 0 nanogram/mL Ready to use. Used for construction of the standard curve. Contains adalimumab(Humira®), human serum, stabilizer and < 0.1% NaN3
  • 1 x 50 mL Assay Buffer Blue colored. Ready to use. Contains proteins and < 0.1% NaN3.
  • 1 x 12 mL HRP CONJHorse radish peroxidase-Conjugated Probe Red colored. Ready to use. Contains HRP-probe, stabilizer and < 0.1% NaN3.
  • 1 x 12 mL TMB SUBSTMB Substrate SolutionReady to use. Contains TMB1 x 12 mL TMB STOPTMB Stop Solution Ready to use. 1N HCl.
  • 1 x 50 mL Wash Buffer, Concentrate (20x) Contains Buffer with Tween 20.
  • 2 x 1 Adhesive Foil For covering of Microtiter Plate during incubation.
  • 2 x 1 Semi-Log Graph Pape rFor constructing standard curve and calculation of results
Material not included
  • Micropipettes (Multipette Eppendorf or similar devices, < 3 % CV).
  • Calibrated measures.
  • Tubes (1 mL) for sample dilution.
  • Wash bottle, automated or semi-automated microtiter plate washing system
  • Microtiter plate reader capable of reading absorbance at 450 nm.
  • Bidistilled or deionised water, paper towels, pipette tips and timer.
Target Type Antibody
Background Adalimumab (Humira®) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor alpha (TNF-a). Adalimumab (Humira®) was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab (Humira®) is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.Adalimumab (Humira®) binds specifically to (TNF-a) and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab (Humira®) also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab (Humira®) does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques.After treatment with adalimumab (Humira®), a decrease in levels of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-6) was observed compared to baseline in patients with rheumatoid arthritis. A decrease in CRP levels was also observed in patients with Crohn's disease. Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodeling responsible for cartilage destruction were also decreased after adalimumab (Humira®) administration.According to the prospectus, the maximum serum concentration (Cmax) and the time to reach the maximum concentration (Tmax) were 4.7 ± 1.6 μg/mL and 131 ± 56 hours respectively, following a single 40 mg subcutaneous administration of Aadalimumab (Humira®) to healthy adult subjects. The average absolute bioavailability of adalimumab (Humira®) estimated from three studies following a single 40 mg subcutaneous dose was 64 % . The pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10.0 mg/kg following a single intravenous dose. The single dose pharmacokinetics of adalimumab in rheumatoid arthritis (RA) patients were determined in several studies with intravenous doses ranging from 0.25 to 10 mg/kg. The distribution volume (Vss) ranged from 4.7 to 6.0 L. The systemic clearance of adalimumab is approximately 12 mL/hr. The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies. Adalimumab concentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to 96 % of those in serum. In RA patients receiving 40 mg adalimumab (Humira®) every other week, adalimumab mean steady-state trough concentrations of approximately 5 μg/mL and 8 to 9 μg/mL, were observed without and with 3 methotrexate (MTX), respectively. In patients with RA, MTX reduced adalimumab apparent clearance after single and multiple dosing by 29 % and 44 % respectively. Mean serum adalimumab trough levels at steady state increased approximately proportionally with dose following 20, 40, and 80 mg every other week and every week subcutaneous dosing. In long-term studies with dosing more than two years, there was no evidence of changes in clearance over time. Adalimumab mean steadystate trough concentrations were slightly higher in psoriatic arthritis patients treated with 40 mg adalimumab (Humira®) every other week (6 to 10 μg/mL and 8.5 to 12 μg/mL, without and with MTX, respectively) compared to the concentrations in RA patients treated with the same dose. The pharmacokinetics of adalimumab in patients with ankylosing spondylitis were similar to those in patients with RA. In patients with Crohn's disease, the loading dose of 160 mg adalimumab (Humira®) on week 0 followed by 80 mg adalimumab (Humira®) on week 2 achieves mean serum adalimumab trough levels of approximately 12 μg/mL at week 2 and week 4. Mean steady-state trough levels of approximately 7 μg/mL were observed at week 24 and week 56 in Crohn's disease patients after receiving a maintenance dose of 40 mg adalimumab (Humira®) every other week. In patients with plaque psoriasis, the mean steady-state trough concentration was approximately 5 to 6 μg/mL during adalimumab 40 mg every other week monotherapy treatment.Population pharmacokinetic analyses in patients with RA revealed that there was a trend toward higher apparent clearance of adalimumab in the presence of antiadalimumab antibodies, and lower clearance with increasing age in patients aged 40 to >75 years. Minor increases in apparent clearance were also predicted in RA patients receiving doses lower than the recommended dose and in RA patients with high rheumatoid factor or CRP concentrations. These increases are reported to be not likely to be clinically important in subjects with juvenile idiopathic arthritis (4 to 17 years of age), the mean steady-state trough serum adalimumab concentrations for subjects weighing <30 kg receiving 20 mg adalimumab (Humira®) subcutaneously every other week as monotherapy or with concomitant methotrexate were 6.8 μg/mL and 10.9 μg/mL, respectively. The mean steady-state trough serum adalimumab concentrations for subjects weighing ≥30 kg receiving 40 mg adalimumab (Humira®) subcutaneously every other week as monotherapy or with concomitant methotrexate were 6.6 μg/mL and 8.1 μg/mL, respectively.It was reported that doses up to 10 mg/kg have been administered to patients in clinical trials without evidence of dose limiting toxicities. However, in case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.However, no pharmacokinetic data are available in patients with hepatic or renal impairment. Serum concentration of adalimumab (Humira®) might be related to predict some clinical outcome during maintenance therapy. It was also possible that the surveillance of circulating adalimumab (Humira®) concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. In this context, identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective minimum concentration of adalimumab (Humira®) in order to potentially avoid some side effects with a reliable method might be beneficial.

  • Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
  • Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
  • Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
  • Use a pipetting scheme to verify an appropriate plate layout.
  • Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
  • Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
  • Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.
    Experiments have shown that the adalimumab ELISA is also suitable to run on an automated ELISA processor.

Sample Volume 20 μL
Assay Time 1 - 2 h
Plate Strips (12 x 8)
Protocol Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and diluted samples (serum or plasma) are incubated in the microtitre plate coated with the reactant for adalimumab (Humira®). After incubation, the wells are washed. A horse radish peroxidase (HRP) conjugated probe is added and binds to adalimumab (Humira®) captured by the reactant on the surface of the wells. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of adalimumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Assay Procedure
  • Pipette 100 μL of Assay Buffer non-exceptionally into each of the wells to be used.
  • Pipette 20 μL of each ready-to use Standards, and Diluted Samples into the respective wells of microtiter plate.
  • Cover the plate with adhesive foil. Incubate 30 min at room temperature (18-25 °C).
  • Remove adhesive foil. Discard incubation solution. Wash plate 3 times each with 300 μL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
  • Pipette 100 μL of ready-to use HRP-Conjugated Probe into each well.
  • Cover the plate with adhesive foil. Incubate 30 min at room temperature (18-25 °C).
  • Remove adhesive foil. Discard incubation solution. Wash plate 3 times each with 300 μL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
  • Pipette 100 μL of TMB Substrate Solution into each well.
  • Incubate 10 min (without adhesive foil.) at room temperature (18-25 °C) in the dark.
  • Stop the substrate reaction by adding 100 μL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
  • Measure optical density with a photometer at 450 nm within 30 min after pipetting of the Stop Solution.
Calculation of Results
  • Either logit-log or semi-log graph paper should be used for manual construction. Construct a standard curve by plotting the OD450 nm for each of 4 standards (disregarding the zero standard) on the vertical linear y-axis versus the corresponding adalimumab (Humira®) concentration on the horizontal logarithmic x-axis, thus create a smooth standard curve with maximum 1 tuning point.
  • The concentration of the samples can be read directly from this standard curve. Using the absorbance value for each sample, determine the corresponding concentration of adalimumab (Humira®) from the standard curve. Find the absorbance value on the Y-axis and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the X-axis and read the adalimumab (Humira®) concentration for the unknown sample.12 • SHIKARI Q-ADA
  • Any sample diluted at 1:10 and still reading greater than the highest standard should be further diluted appropriately with Assay Buffer and retested. Because the samples have been diluted, the concentration determined from the standard-curve must be multiplied by the dilution factor.Typical Calibration Curve(Example. Do not use for calculation!)Standard Concentration(ng/mL) Mean OD450A 1000 2,200B 300 0,920C 100 0,420D 30 0,180E 0 0,055
Assay Precision Intra-assay CV: <8% for adalimumab range 30-1000 ng/mL.Inter-assay CV: <8% for adalimumab range 30-1000 ng/mL.
Restrictions For Research Use only
Buffer < 0.1 % sodium azide
Preservative Sodium azide
Precaution of Use protect your eyes, wear lab gloves
Handling Advice
  • For research and professional use only.
  • Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
  • In case of severe damage of the kit package please contact or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
  • Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
  • Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
  • Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
  • Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
  • Avoid contact with Stop solution. It may cause skin irritations and burns.
  • All reagents of this kit containing human serum or plasma (i.e. standards) have been tested and were found negative for HIV I/II, HBsAg and HCV. However, a presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.1
  • Some reagents contain sodium azide (NaN3) as preservatives. In case of contact with eyes or skin, flush immediately with water. NaN3 may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with large volume of water to avoid azide build-up.
Storage 4 °C
Storage Comment The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The strips of microtiter plate is stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.
Expiry Date 12 months
Supplier Images
ELISA image for Adalimumab ELISA Kit (ABIN1540249) Typical Calibration Curve
Product cited in: Bodini, Giannini, Savarino et al.: "Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice." in: The American journal of gastroenterology, Vol. 110, Issue 3, pp. 472-3, 2015 (PubMed).

Bortlik, Duricova, Machkova et al.: "Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children." in: Inflammatory bowel diseases, Vol. 20, Issue 3, pp. 495-501, 2014 (PubMed).

Romero, Ochoteco, Sanz et al.: "Poly(lactide-co-glycolide) nanoparticles, layer by layer engineered for the sustainable delivery of antiTNF-α." in: Macromolecular bioscience, Vol. 13, Issue 7, pp. 903-12, 2013 (PubMed).

Background publications Ghate, Alspaugh: "Adalimumab in the management of palmoplantar psoriasis." in: Journal of drugs in dermatology : JDD, Vol. 8, Issue 12, pp. 1136-9, 2009 (PubMed).

Jürgens, Brand, Filik et al.: "Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature." in: Inflammatory bowel diseases, Vol. 16, Issue 10, pp. 1634-6, 2010 (PubMed).

Murphy, Schmidt-Martin, Hynes et al.: "Systemic listeriosis with adalimumab therapy." in: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 15, Issue 7, pp. 369-70, 2009 (PubMed).

Martorell-Calatayud, Balmer, Cardenas Cardona et al.: "Interstitial granulomatous drug reaction to adalimumab." in: The American Journal of dermatopathology, Vol. 32, Issue 4, pp. 408-9, 2010 (PubMed).

Mease, Signorovitch, Yu et al.: "Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials." in: Dermatology (Basel, Switzerland), Vol. 220, Issue 1, pp. 1-7, 2010 (PubMed).

Wetter, Davis: "Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic." in: Mayo Clinic proceedings, Vol. 84, Issue 11, pp. 979-84, 2009 (PubMed).

Borrás-Blasco, Navarro-Ruiz, Borrás et al.: "Adverse cutaneous reactions induced by TNF-alpha antagonist therapy." in: Southern medical journal, Vol. 102, Issue 11, pp. 1133-40, 2009 (PubMed).

Patel: "Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report." in: Journal of medical case reports, Vol. 3, pp. 8573, 2009 (PubMed).

de Vries, Brouwer, van der Horst-Bruinsma et al.: "Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation." in: Annals of the rheumatic diseases, Vol. 68, Issue 11, pp. 1787-8, 2009 (PubMed).

Murdaca, Colombo, Puppo: "Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events." in: International journal of immunopathology and pharmacology, Vol. 22, Issue 3, pp. 557-65, 2009 (PubMed).

Turner, Picot, Cooper et al.: "Adalimumab for the treatment of psoriasis." in: Health technology assessment (Winchester, England), Vol. 13 Suppl 2, pp. 49-54, 2009 (PubMed).

Varani, Massara, Vincenzi et al.: "Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate." in: Arthritis and rheumatism, Vol. 60, Issue 10, pp. 2880-91, 2009 (PubMed).

Yildiz, Alkan, Ardic et al.: "Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis." in: Rheumatology international, Vol. 30, Issue 11, pp. 1511-4, 2010 (PubMed).

Tong, Eather, Manolios: "Psoriatic arthritis and chronic lymphoedema: treatment efficacy by adalimumab." in: Clinical rheumatology, Vol. 28, Issue 11, pp. 1349-50, 2009 (PubMed).

Bradford, Pettit, Wright et al.: "Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors." in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 49, Issue 6, pp. 924-7, 2009 (PubMed).

Barreiro-de Acosta, Lorenzo, Dominguez-Muñoz: "Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years." in: World journal of gastroenterology : WJG, Vol. 15, Issue 30, pp. 3814-6, 2009 (PubMed).

Karmiris, Paintaud, Noman et al.: "Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease." in: Gastroenterology, Vol. 137, Issue 5, pp. 1628-40, 2009 (PubMed).

Papadakis, Shaye, Vasiliauskas et al.: "Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab." in: The American journal of gastroenterology, Vol. 100, Issue 1, pp. 75-9, 2005 (PubMed).

Sandborn: "Strategies for targeting tumour necrosis factor in IBD." in: Best practice & research. Clinical gastroenterology, Vol. 17, Issue 1, pp. 105-17, 2003 (PubMed).

Taylor: "Anti-TNFalpha therapy for rheumatoid arthritis: an update." in: Internal medicine (Tokyo, Japan), Vol. 42, Issue 1, pp. 15-20, 2003 (PubMed).

Weinblatt, Keystone, Furst et al.: "Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial." in: Arthritis and rheumatism, Vol. 48, Issue 1, pp. 35-45, 2003 (PubMed).

Catalog No. ABIN1540249
Plus shipping costs $45.00

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)